Zymeworks pockets $15M, woos Lilly with its double-barreled antibodies FierceBiotech Under the deal, Lilly gets a worldwide license to the technology and commercial rights to any antibodies derived from the partnership, while Zymeworks snags an undisclosed upfront fee, research support, milestone payments and royalties on future sales. Lilly Licenses Zymeworks Technology to Develop Bi-specific Antibodies Zymeworks Inc. Announces Strategic Collaboration with Lilly Subsidiary ImClone ... Zymeworks Announces $15.0 Million Private Placement Financing to Advance ... |
